Share Price and Basic Stock Data
Last Updated: December 12, 2025, 5:57 pm
| PEG Ratio | -3.39 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Kopran Ltd operates within the pharmaceutical sector and has shown a commendable trajectory in its revenue generation. For the financial year ending March 2025, the company reported sales of ₹630 Cr, marking a notable increase from ₹551 Cr in FY 2023. This upward trend reflects a consistent growth pattern, particularly in the latter part of the fiscal year, where quarterly sales peaked at ₹186.08 Cr in March 2024. However, the data indicates fluctuations throughout the quarters, with some dips, such as the drop to ₹117 Cr in June 2023. These variations could suggest seasonal impacts or operational challenges that the company needs to address to stabilize revenue streams. Overall, the revenue growth trajectory appears strong, supported by a larger market for pharmaceuticals and an increasing demand for healthcare solutions in India.
Profitability and Efficiency Metrics
Kopran’s profitability metrics tell a mixed story. The company recorded a net profit of ₹39 Cr for FY 2025, down from ₹51 Cr in FY 2024. This decline can be attributed to rising operational expenses, which stood at ₹557 Cr in FY 2025, compared to ₹540 Cr the previous year. The operating profit margin (OPM) stabilized at 12%, a slight improvement from the previous year’s 12%. However, the net profit margin fell to 6.12%, down from 8.29% in FY 2024. This trend raises concerns about operational efficiency, particularly the increasing cost pressures. On an efficiency front, the interest coverage ratio stood at 8.23x, indicating that the company can comfortably meet its interest obligations, a reassuring sign for stakeholders. Yet, the cash conversion cycle of 170 days suggests lingering inefficiencies in inventory management and receivables collection that Kopran must address to improve cash flow.
Balance Sheet Strength and Financial Ratios
The balance sheet of Kopran Ltd reveals a company that is relatively stable but is also experiencing a rise in borrowings, which stood at ₹157 Cr as of March 2025, up from ₹99 Cr in FY 2024. This increase in debt may raise questions about financial leverage and risk, especially when considering that total liabilities reached ₹844 Cr in the same period. The company maintains a current ratio of 1.76, which indicates a comfortable liquidity position, allowing it to cover its short-term obligations. The return on equity (ROE) was recorded at 7.43%, which, while positive, is somewhat modest compared to industry standards. Additionally, the price-to-book ratio of 1.63x suggests that the stock is trading at a premium relative to its book value, potentially reflecting investor confidence but also raising concerns about valuation levels. Overall, while the balance sheet shows resilience, the rising debt levels could pose future challenges.
Shareholding Pattern and Investor Confidence
The shareholding structure of Kopran Ltd reveals significant public participation, with 54.99% of shares held by the public as of March 2025. Promoter holdings stood at 44.43%, which reflects a stable commitment by the founding shareholders. However, foreign institutional investors (FIIs) and domestic institutional investors (DIIs) have minimal exposure, with FIIs at just 0.60% and DIIs at 0%. This lack of institutional investment could indicate a cautious sentiment among larger investors, possibly due to perceived risks or valuation concerns. The number of shareholders has steadily increased, reaching 62,222, which is a positive indicator of growing retail interest. However, investor confidence may hinge on the company’s ability to enhance profitability and operational efficiency, especially in an increasingly competitive pharmaceutical landscape.
Outlook, Risks, and Final Insight
Looking ahead, Kopran Ltd is positioned in a growing sector, but several risks could affect its trajectory. Operational efficiency remains a critical area for improvement, particularly in managing costs and optimizing the cash conversion cycle. Additionally, the company’s rising debt levels could become a concern if not managed judiciously, especially in a fluctuating market. The competitive landscape in pharmaceuticals is also intensifying, necessitating continuous innovation and effective marketing strategies. Investors should weigh these risks against the potential for growth in a sector that is essential for public health. Overall, while Kopran Ltd has strengths such as a solid revenue trajectory and a stable balance sheet, the company must navigate challenges effectively to sustain investor confidence and drive long-term growth.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 146 Cr. | 116 | 239/84.3 | 32.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,249 Cr. | 390 | 479/192 | 88.0 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.1 Cr. | 44.6 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 44.0 Cr. | 30.1 | 31.0/17.0 | 105 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,467.57 Cr | 1,156.55 | 51.99 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 125.62 | 116.97 | 158.00 | 148.88 | 117.00 | 152.59 | 158.92 | 186.08 | 139.44 | 151.56 | 166.24 | 172.36 | 135.22 |
| Expenses | 112.46 | 106.83 | 145.68 | 136.72 | 110.69 | 129.76 | 135.34 | 164.39 | 121.28 | 136.83 | 146.39 | 155.27 | 121.09 |
| Operating Profit | 13.16 | 10.14 | 12.32 | 12.16 | 6.31 | 22.83 | 23.58 | 21.69 | 18.16 | 14.73 | 19.85 | 17.09 | 14.13 |
| OPM % | 10.48% | 8.67% | 7.80% | 8.17% | 5.39% | 14.96% | 14.84% | 11.66% | 13.02% | 9.72% | 11.94% | 9.92% | 10.45% |
| Other Income | 0.65 | 0.44 | 2.22 | 3.78 | 2.39 | 0.13 | 2.43 | 9.67 | 2.63 | 1.00 | 0.17 | 3.26 | 2.56 |
| Interest | 0.79 | 1.28 | 2.24 | 1.78 | 1.83 | 1.94 | 2.24 | 2.59 | 2.18 | 2.23 | 2.16 | 2.77 | 2.54 |
| Depreciation | 3.05 | 3.25 | 3.16 | 3.24 | 3.26 | 2.77 | 3.27 | 3.59 | 3.87 | 3.85 | 4.00 | 3.87 | 4.26 |
| Profit before tax | 9.97 | 6.05 | 9.14 | 10.92 | 3.61 | 18.25 | 20.50 | 25.18 | 14.74 | 9.65 | 13.86 | 13.71 | 9.89 |
| Tax % | 23.77% | 23.14% | 23.96% | 26.37% | 22.99% | 24.55% | 23.02% | 26.01% | 24.69% | 23.42% | 24.96% | 29.39% | 24.67% |
| Net Profit | 7.60 | 4.65 | 6.95 | 8.04 | 2.77 | 13.77 | 15.79 | 18.62 | 11.10 | 7.38 | 10.40 | 9.68 | 7.45 |
| EPS in Rs | 1.58 | 0.96 | 1.44 | 1.67 | 0.57 | 2.86 | 3.28 | 3.86 | 2.30 | 1.53 | 2.16 | 2.01 | 1.54 |
Last Updated: August 1, 2025, 6:15 pm
Below is a detailed analysis of the quarterly data for Kopran Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 135.22 Cr.. The value appears to be declining and may need further review. It has decreased from 172.36 Cr. (Mar 2025) to 135.22 Cr., marking a decrease of 37.14 Cr..
- For Expenses, as of Jun 2025, the value is 121.09 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 155.27 Cr. (Mar 2025) to 121.09 Cr., marking a decrease of 34.18 Cr..
- For Operating Profit, as of Jun 2025, the value is 14.13 Cr.. The value appears to be declining and may need further review. It has decreased from 17.09 Cr. (Mar 2025) to 14.13 Cr., marking a decrease of 2.96 Cr..
- For OPM %, as of Jun 2025, the value is 10.45%. The value appears strong and on an upward trend. It has increased from 9.92% (Mar 2025) to 10.45%, marking an increase of 0.53%.
- For Other Income, as of Jun 2025, the value is 2.56 Cr.. The value appears to be declining and may need further review. It has decreased from 3.26 Cr. (Mar 2025) to 2.56 Cr., marking a decrease of 0.70 Cr..
- For Interest, as of Jun 2025, the value is 2.54 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.77 Cr. (Mar 2025) to 2.54 Cr., marking a decrease of 0.23 Cr..
- For Depreciation, as of Jun 2025, the value is 4.26 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.87 Cr. (Mar 2025) to 4.26 Cr., marking an increase of 0.39 Cr..
- For Profit before tax, as of Jun 2025, the value is 9.89 Cr.. The value appears to be declining and may need further review. It has decreased from 13.71 Cr. (Mar 2025) to 9.89 Cr., marking a decrease of 3.82 Cr..
- For Tax %, as of Jun 2025, the value is 24.67%. The value appears to be improving (decreasing) as expected. It has decreased from 29.39% (Mar 2025) to 24.67%, marking a decrease of 4.72%.
- For Net Profit, as of Jun 2025, the value is 7.45 Cr.. The value appears to be declining and may need further review. It has decreased from 9.68 Cr. (Mar 2025) to 7.45 Cr., marking a decrease of 2.23 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.54. The value appears to be declining and may need further review. It has decreased from 2.01 (Mar 2025) to 1.54, marking a decrease of 0.47.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:59 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 303 | 326 | 296 | 310 | 313 | 358 | 360 | 492 | 478 | 551 | 615 | 630 | 625 |
| Expenses | 260 | 294 | 266 | 274 | 283 | 312 | 313 | 410 | 390 | 499 | 540 | 557 | 560 |
| Operating Profit | 43 | 31 | 30 | 36 | 31 | 46 | 47 | 82 | 87 | 52 | 74 | 73 | 66 |
| OPM % | 14% | 10% | 10% | 12% | 10% | 13% | 13% | 17% | 18% | 9% | 12% | 12% | 11% |
| Other Income | 2 | -48 | 1 | 11 | 9 | 3 | -0 | 18 | 11 | 3 | 15 | 4 | 7 |
| Interest | 14 | 13 | 13 | 14 | 9 | 9 | 9 | 6 | 5 | 6 | 9 | 9 | 10 |
| Depreciation | 13 | 10 | 8 | 8 | 9 | 9 | 10 | 10 | 11 | 13 | 13 | 16 | 16 |
| Profit before tax | 17 | -39 | 11 | 25 | 23 | 32 | 28 | 83 | 82 | 36 | 68 | 52 | 47 |
| Tax % | 0% | 0% | 0% | 20% | 10% | 24% | 26% | 26% | 25% | 24% | 25% | 26% | |
| Net Profit | 17 | -39 | 11 | 20 | 20 | 24 | 21 | 62 | 61 | 27 | 51 | 39 | 35 |
| EPS in Rs | 4.40 | -9.52 | 2.48 | 4.60 | 4.74 | 5.55 | 4.86 | 14.24 | 12.66 | 5.65 | 10.57 | 7.99 | 7.24 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 21% | 24% | 53% | 28% | 38% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -329.41% | 128.21% | 81.82% | 0.00% | 20.00% | -12.50% | 195.24% | -1.61% | -55.74% | 88.89% | -23.53% |
| Change in YoY Net Profit Growth (%) | 0.00% | 457.62% | -46.39% | -81.82% | 20.00% | -32.50% | 207.74% | -196.85% | -54.12% | 144.63% | -112.42% |
Kopran Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 12% |
| 3 Years: | 10% |
| TTM: | -2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 12% |
| 3 Years: | -14% |
| TTM: | -41% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 18% |
| 3 Years: | -2% |
| 1 Year: | -51% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 12% |
| 3 Years: | 8% |
| Last Year: | 8% |
Last Updated: September 5, 2025, 9:15 am
Balance Sheet
Last Updated: December 4, 2025, 1:32 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 39 | 41 | 43 | 43 | 43 | 43 | 43 | 43 | 48 | 48 | 48 | 48 | 48 |
| Reserves | 67 | 49 | 57 | 81 | 101 | 125 | 146 | 202 | 378 | 391 | 443 | 470 | 453 |
| Borrowings | 137 | 86 | 80 | 95 | 89 | 97 | 88 | 66 | 75 | 75 | 99 | 148 | 157 |
| Other Liabilities | 56 | 99 | 84 | 78 | 82 | 85 | 92 | 128 | 110 | 135 | 153 | 178 | 155 |
| Total Liabilities | 299 | 275 | 264 | 298 | 315 | 351 | 370 | 439 | 611 | 650 | 743 | 844 | 813 |
| Fixed Assets | 105 | 102 | 101 | 104 | 104 | 113 | 111 | 112 | 151 | 165 | 182 | 208 | 235 |
| CWIP | 20 | 1 | 3 | 6 | 10 | 24 | 30 | 43 | 36 | 70 | 97 | 113 | 114 |
| Investments | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 174 | 172 | 160 | 187 | 201 | 214 | 229 | 284 | 425 | 415 | 465 | 522 | 465 |
| Total Assets | 299 | 275 | 264 | 298 | 315 | 351 | 370 | 439 | 611 | 650 | 743 | 844 | 813 |
Below is a detailed analysis of the balance sheet data for Kopran Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 48.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 48.00 Cr..
- For Reserves, as of Sep 2025, the value is 453.00 Cr.. The value appears to be declining and may need further review. It has decreased from 470.00 Cr. (Mar 2025) to 453.00 Cr., marking a decrease of 17.00 Cr..
- For Borrowings, as of Sep 2025, the value is 157.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 148.00 Cr. (Mar 2025) to 157.00 Cr., marking an increase of 9.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 155.00 Cr.. The value appears to be improving (decreasing). It has decreased from 178.00 Cr. (Mar 2025) to 155.00 Cr., marking a decrease of 23.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 813.00 Cr.. The value appears to be improving (decreasing). It has decreased from 844.00 Cr. (Mar 2025) to 813.00 Cr., marking a decrease of 31.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 235.00 Cr.. The value appears strong and on an upward trend. It has increased from 208.00 Cr. (Mar 2025) to 235.00 Cr., marking an increase of 27.00 Cr..
- For CWIP, as of Sep 2025, the value is 114.00 Cr.. The value appears strong and on an upward trend. It has increased from 113.00 Cr. (Mar 2025) to 114.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 465.00 Cr.. The value appears to be declining and may need further review. It has decreased from 522.00 Cr. (Mar 2025) to 465.00 Cr., marking a decrease of 57.00 Cr..
- For Total Assets, as of Sep 2025, the value is 813.00 Cr.. The value appears to be declining and may need further review. It has decreased from 844.00 Cr. (Mar 2025) to 813.00 Cr., marking a decrease of 31.00 Cr..
Notably, the Reserves (453.00 Cr.) exceed the Borrowings (157.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -94.00 | -55.00 | -50.00 | -59.00 | -58.00 | -51.00 | -41.00 | 16.00 | 12.00 | -23.00 | -25.00 | -75.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 68 | 91 | 70 | 86 | 75 | 88 | 94 | 89 | 97 | 108 | 126 | 125 |
| Inventory Days | 103 | 78 | 119 | 122 | 138 | 129 | 154 | 121 | 202 | 133 | 126 | 153 |
| Days Payable | 69 | 119 | 115 | 95 | 118 | 90 | 95 | 104 | 84 | 89 | 103 | 108 |
| Cash Conversion Cycle | 101 | 50 | 74 | 113 | 96 | 127 | 153 | 106 | 215 | 152 | 149 | 170 |
| Working Capital Days | 45 | 9 | 34 | 43 | 60 | 70 | 79 | 81 | 158 | 139 | 131 | 113 |
| ROCE % | 14% | 14% | 14% | 19% | 14% | 16% | 14% | 30% | 21% | 8% | 14% | 10% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Healthcare Fund | 101,067 | 1.41 | 2.28 | 101,067 | 2025-04-22 17:25:28 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 251 | 0.07 | 0.01 | 251 | 2025-04-22 17:25:28 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 7.99 | 10.57 | 5.65 | 13.77 | 14.24 |
| Diluted EPS (Rs.) | 7.99 | 10.57 | 5.65 | 13.77 | 14.24 |
| Cash EPS (Rs.) | 11.21 | 13.24 | 8.29 | 14.96 | 16.60 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 107.35 | 101.90 | 91.11 | 88.40 | 56.65 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 107.35 | 101.90 | 91.11 | 88.40 | 56.65 |
| Revenue From Operations / Share (Rs.) | 130.39 | 127.48 | 114.29 | 99.05 | 113.71 |
| PBDIT / Share (Rs.) | 15.92 | 18.47 | 11.38 | 20.33 | 23.07 |
| PBIT / Share (Rs.) | 12.69 | 15.79 | 8.74 | 18.02 | 20.71 |
| PBT / Share (Rs.) | 10.76 | 14.01 | 7.48 | 16.96 | 19.27 |
| Net Profit / Share (Rs.) | 7.98 | 10.57 | 5.65 | 12.66 | 14.24 |
| NP After MI And SOA / Share (Rs.) | 7.98 | 10.57 | 5.65 | 12.66 | 14.24 |
| PBDIT Margin (%) | 12.21 | 14.48 | 9.95 | 20.52 | 20.28 |
| PBIT Margin (%) | 9.73 | 12.38 | 7.64 | 18.19 | 18.21 |
| PBT Margin (%) | 8.25 | 10.99 | 6.54 | 17.12 | 16.94 |
| Net Profit Margin (%) | 6.12 | 8.29 | 4.94 | 12.78 | 12.52 |
| NP After MI And SOA Margin (%) | 6.12 | 8.29 | 4.94 | 12.78 | 12.52 |
| Return on Networth / Equity (%) | 7.43 | 10.37 | 6.19 | 14.32 | 25.14 |
| Return on Capital Employeed (%) | 11.04 | 14.51 | 8.91 | 18.91 | 32.14 |
| Return On Assets (%) | 4.56 | 6.85 | 4.19 | 9.99 | 14.02 |
| Long Term Debt / Equity (X) | 0.03 | 0.03 | 0.04 | 0.04 | 0.08 |
| Total Debt / Equity (X) | 0.28 | 0.20 | 0.17 | 0.17 | 0.26 |
| Asset Turnover Ratio (%) | 0.79 | 0.88 | 0.87 | 0.45 | 0.64 |
| Current Ratio (X) | 1.76 | 2.08 | 2.25 | 2.74 | 1.72 |
| Quick Ratio (X) | 1.18 | 1.44 | 1.52 | 1.75 | 1.10 |
| Inventory Turnover Ratio (X) | 4.09 | 2.93 | 2.29 | 1.82 | 1.81 |
| Dividend Payout Ratio (NP) (%) | 37.51 | 28.38 | 53.10 | 10.62 | 10.53 |
| Dividend Payout Ratio (CP) (%) | 26.71 | 22.65 | 36.20 | 8.99 | 9.03 |
| Earning Retention Ratio (%) | 62.49 | 71.62 | 46.90 | 89.38 | 89.47 |
| Cash Earning Retention Ratio (%) | 73.29 | 77.35 | 63.80 | 91.01 | 90.97 |
| Interest Coverage Ratio (X) | 8.23 | 10.36 | 9.02 | 19.15 | 15.99 |
| Interest Coverage Ratio (Post Tax) (X) | 5.13 | 6.93 | 5.48 | 12.93 | 10.87 |
| Enterprise Value (Cr.) | 967.40 | 1330.79 | 595.14 | 1372.72 | 511.32 |
| EV / Net Operating Revenue (X) | 1.54 | 2.17 | 1.08 | 2.87 | 1.04 |
| EV / EBITDA (X) | 12.58 | 14.95 | 10.85 | 14.01 | 5.13 |
| MarketCap / Net Operating Revenue (X) | 1.34 | 2.03 | 0.96 | 2.84 | 0.92 |
| Retention Ratios (%) | 62.48 | 71.61 | 46.89 | 89.37 | 89.46 |
| Price / BV (X) | 1.63 | 2.54 | 1.21 | 3.19 | 1.85 |
| Price / Net Operating Revenue (X) | 1.34 | 2.03 | 0.96 | 2.84 | 0.92 |
| EarningsYield | 0.04 | 0.04 | 0.05 | 0.04 | 0.13 |
After reviewing the key financial ratios for Kopran Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 7.99. This value is within the healthy range. It has decreased from 10.57 (Mar 24) to 7.99, marking a decrease of 2.58.
- For Diluted EPS (Rs.), as of Mar 25, the value is 7.99. This value is within the healthy range. It has decreased from 10.57 (Mar 24) to 7.99, marking a decrease of 2.58.
- For Cash EPS (Rs.), as of Mar 25, the value is 11.21. This value is within the healthy range. It has decreased from 13.24 (Mar 24) to 11.21, marking a decrease of 2.03.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 107.35. It has increased from 101.90 (Mar 24) to 107.35, marking an increase of 5.45.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 107.35. It has increased from 101.90 (Mar 24) to 107.35, marking an increase of 5.45.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 130.39. It has increased from 127.48 (Mar 24) to 130.39, marking an increase of 2.91.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 15.92. This value is within the healthy range. It has decreased from 18.47 (Mar 24) to 15.92, marking a decrease of 2.55.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.69. This value is within the healthy range. It has decreased from 15.79 (Mar 24) to 12.69, marking a decrease of 3.10.
- For PBT / Share (Rs.), as of Mar 25, the value is 10.76. This value is within the healthy range. It has decreased from 14.01 (Mar 24) to 10.76, marking a decrease of 3.25.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 7.98. This value is within the healthy range. It has decreased from 10.57 (Mar 24) to 7.98, marking a decrease of 2.59.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 7.98. This value is within the healthy range. It has decreased from 10.57 (Mar 24) to 7.98, marking a decrease of 2.59.
- For PBDIT Margin (%), as of Mar 25, the value is 12.21. This value is within the healthy range. It has decreased from 14.48 (Mar 24) to 12.21, marking a decrease of 2.27.
- For PBIT Margin (%), as of Mar 25, the value is 9.73. This value is below the healthy minimum of 10. It has decreased from 12.38 (Mar 24) to 9.73, marking a decrease of 2.65.
- For PBT Margin (%), as of Mar 25, the value is 8.25. This value is below the healthy minimum of 10. It has decreased from 10.99 (Mar 24) to 8.25, marking a decrease of 2.74.
- For Net Profit Margin (%), as of Mar 25, the value is 6.12. This value is within the healthy range. It has decreased from 8.29 (Mar 24) to 6.12, marking a decrease of 2.17.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.12. This value is below the healthy minimum of 8. It has decreased from 8.29 (Mar 24) to 6.12, marking a decrease of 2.17.
- For Return on Networth / Equity (%), as of Mar 25, the value is 7.43. This value is below the healthy minimum of 15. It has decreased from 10.37 (Mar 24) to 7.43, marking a decrease of 2.94.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.04. This value is within the healthy range. It has decreased from 14.51 (Mar 24) to 11.04, marking a decrease of 3.47.
- For Return On Assets (%), as of Mar 25, the value is 4.56. This value is below the healthy minimum of 5. It has decreased from 6.85 (Mar 24) to 4.56, marking a decrease of 2.29.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.03.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.28. This value is within the healthy range. It has increased from 0.20 (Mar 24) to 0.28, marking an increase of 0.08.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.79. It has decreased from 0.88 (Mar 24) to 0.79, marking a decrease of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 1.76. This value is within the healthy range. It has decreased from 2.08 (Mar 24) to 1.76, marking a decrease of 0.32.
- For Quick Ratio (X), as of Mar 25, the value is 1.18. This value is within the healthy range. It has decreased from 1.44 (Mar 24) to 1.18, marking a decrease of 0.26.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.09. This value is within the healthy range. It has increased from 2.93 (Mar 24) to 4.09, marking an increase of 1.16.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 37.51. This value is within the healthy range. It has increased from 28.38 (Mar 24) to 37.51, marking an increase of 9.13.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 26.71. This value is within the healthy range. It has increased from 22.65 (Mar 24) to 26.71, marking an increase of 4.06.
- For Earning Retention Ratio (%), as of Mar 25, the value is 62.49. This value is within the healthy range. It has decreased from 71.62 (Mar 24) to 62.49, marking a decrease of 9.13.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 73.29. This value exceeds the healthy maximum of 70. It has decreased from 77.35 (Mar 24) to 73.29, marking a decrease of 4.06.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.23. This value is within the healthy range. It has decreased from 10.36 (Mar 24) to 8.23, marking a decrease of 2.13.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.13. This value is within the healthy range. It has decreased from 6.93 (Mar 24) to 5.13, marking a decrease of 1.80.
- For Enterprise Value (Cr.), as of Mar 25, the value is 967.40. It has decreased from 1,330.79 (Mar 24) to 967.40, marking a decrease of 363.39.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.54. This value is within the healthy range. It has decreased from 2.17 (Mar 24) to 1.54, marking a decrease of 0.63.
- For EV / EBITDA (X), as of Mar 25, the value is 12.58. This value is within the healthy range. It has decreased from 14.95 (Mar 24) to 12.58, marking a decrease of 2.37.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.34. This value is within the healthy range. It has decreased from 2.03 (Mar 24) to 1.34, marking a decrease of 0.69.
- For Retention Ratios (%), as of Mar 25, the value is 62.48. This value is within the healthy range. It has decreased from 71.61 (Mar 24) to 62.48, marking a decrease of 9.13.
- For Price / BV (X), as of Mar 25, the value is 1.63. This value is within the healthy range. It has decreased from 2.54 (Mar 24) to 1.63, marking a decrease of 0.91.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.34. This value is within the healthy range. It has decreased from 2.03 (Mar 24) to 1.34, marking a decrease of 0.69.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Kopran Ltd:
- Net Profit Margin: 6.12%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.04% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 7.43% (Industry Average ROE: 14.71%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.13
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.18
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 35.9 (Industry average Stock P/E: 42.76)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.28
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.12%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Parijat House, 1076, Dr. E. Moses Road, Mumbai Maharashtra 400018 | investors@kopran.com http://www.kopran.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Susheel G Somani | Chairman |
| Mr. Surendra Somani | Executive Vice Chairman |
| Mr. Adarsh Somani | Director |
| Mr. Varun Somani | Director |
| Dr. Siddhan Subramanian | Independent Director |
| Dr. Sunita Banerji | Independent Director |
| Mrs. Mamta Biyani | Independent Director |
| Mr. Narayan Atal | Independent Director |
FAQ
What is the intrinsic value of Kopran Ltd?
Kopran Ltd's intrinsic value (as of 12 December 2025) is 233.42 which is 78.18% higher the current market price of 131.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 632 Cr. market cap, FY2025-2026 high/low of 227/123, reserves of ₹453 Cr, and liabilities of 813 Cr.
What is the Market Cap of Kopran Ltd?
The Market Cap of Kopran Ltd is 632 Cr..
What is the current Stock Price of Kopran Ltd as on 12 December 2025?
The current stock price of Kopran Ltd as on 12 December 2025 is 131.
What is the High / Low of Kopran Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Kopran Ltd stocks is 227/123.
What is the Stock P/E of Kopran Ltd?
The Stock P/E of Kopran Ltd is 35.9.
What is the Book Value of Kopran Ltd?
The Book Value of Kopran Ltd is 104.
What is the Dividend Yield of Kopran Ltd?
The Dividend Yield of Kopran Ltd is 2.29 %.
What is the ROCE of Kopran Ltd?
The ROCE of Kopran Ltd is 9.75 %.
What is the ROE of Kopran Ltd?
The ROE of Kopran Ltd is 7.64 %.
What is the Face Value of Kopran Ltd?
The Face Value of Kopran Ltd is 10.0.